Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Naitee Ting, Allison Brailey Pfizer Global R&D CT Chapter Mini Conference
1
Outline
Last Observation Carried Forward (LOCF) Data set description Modeling approaches Concerns in clinical Trials SAP concerns Why or why not use LOCF
2
Patients
0
10
Complete Data
13 12 11
VAS Pain
10 9 8 7 6 0 1 2 3 4 5 6
PID 1 PID 2 PID 3 PID 4
Visits
4
Last-Observation-CarriedForward
13 12 11 10 9 8 7 6 0 1 2 3 4 5 6
PID 1 PID 2 PID 3 PID 4
VAS Pain
Visits
5
LOCF
75
70
65
60
55
75
70
65
60
55
Data set
Simulated - standing diastolic BP Eight week study of test drug vs placebo Clinic visit every 2 weeks Primary endpoint change in standing BP from baseline to week 8 Patients completed the study or dropped out at various time points Missing completely at random
9
Simulated data
ctr 501 501 501 501 501 501 501 501 502 502 502 502 502 502 502 502
pid 1 2 5 6 11 15 16 18 1 4 5 8 9 12 13 16
trt 1 0 0 1 0 0 1 0 0 1 1 0 1 0 0 1
wk0 103.9 105.9 93.8 102.8 109.4 93.9 92.4 99.3 105.8 102.0 110.3 125.6 92.9 123.7 107.7 112.1
wk2 102.0 111.8 98.4 87.4 105.3 81.6 83.6 99.0 102.7 100.3 116.8 121.7 91.4 121.7 121.4 109.6
wk4 103.6 112.5 103.4 72.8 99.2 66.1 71.7 101.9 87.5 101.1 120.6 116.1 82.1 118.3 141.5 103.6
wk6 102.2 115.0 104.5 60.9 96.9 50.5 66.2 102.5 84.9 95.7 132.7 110.0 . 122.0 154.7 103.3
wk8 100.4 117.0 116.7 48.5 89.7 40.3 56.5 103.2 78.8 . 136.8 108.5 . 120.3 168.9 104.2
10
Modeling approaches
Source TREATMENT CENTER BASELINE ERROR Statistic Raw Mean Adj Mean Std Error N
| df | 1 | 8 | 1 |119
12
Source TREATMENT CENTER BASELINE ERROR Statistic Raw Mean Adj Mean Std Error N
| df | 1 | 8 | 1 |109
13
Naive interpretation
If LOCF provides statistical significance If completer analysis supports LOCF True story may lie between the two Clinical conclusion can be made
14
15
Effect
Num DF 1 1 8 3 3
F Value
Pr > F
0.0826 0.0313 <.0001 0.0662 0.3132 t Value 2.45 Pr > |t| 0.0183
3.03 5.57 5.43 2.46 1.22 Standard Estimate Error DF 7.3739 3.0127 46
16
Mixed model can be considered as single imputation For imputation, we can use the same model for imputation and analysis However, one model can be used for imputation, but a different one is for analysis
17
After the modeling approaches became available, use of LOCF have been discouraged Models are developed with assumptions More complicated models require more assumptions Are these assumptions justified?
18
LOCF is a model and there are simple assumptions behind it In New Drug Applications (NDA), LOCF is still widely used Why?
19
20
Double-blind, placebo controlled, randomized clinical trial Test hypothesis - does the drug work? Null hypothesis (H0) - no difference between test drug and placebo Alternative hypothesis (Ha) - there is a difference
21
TYPES OF ERRORS
Regulatory agencies focus on the control of Type I error Probability of making a Type I error is not greater than a In general, a = 0.05; i.e., 1 in 20 Avoid inflation of this error Changing the method of analysis to fit data will inflate a
22
MULTIPLE COMPARISONS
For 20 independent variables (clinical endpoints), one significant at random For 20 independent treatment comparisons, one significant at random Subgroup analyses can also potentially inflate a Multiple comparison adjustment
23
Scientific experiments generate data Outliers may be observed Delete outlier? Clinical trials generate data A wonder drug cures 9,999 patients of 10,000 One died outlier delete?
24
Pre-specification of analysis Prior to breaking blind Internal agreement within project team Binding document to communicate with regulatory authorities Use of LOCF or modeling approach need to be pre-specified in SAP
25
Modeling approaches
Assumptions Can be complicated Difficult to explain to end users George Box All models are wrong, some are useful
26
Easy to understand Easy to communicate between statisticians and clinicians, and between sponsor and regulators Lots of prior examples Biased point estimate, biased variance
27
Recommendations
Understand the disease Understand data to be collected Understand the dropout issues Make use of Phase II results Encourage use of statistical models LOCF may still be considered as supportive
28
29